Cabozantinib and apixaban: an hitherto unreported interaction

The use of direct oral anticoagulant in cancer patients is an emerging issue, which seems to be an alternative to low molecular weight heparin. Every year several new drugs are approved as anticancer treatment with possible drug-drug interaction with other drugs such as oral anticoagulant. We descri...

Descripción completa

Detalles Bibliográficos
Autores principales: Santini, Daniele, Citarella, Fabrizio, Vincenzi, Bruno, Russano, Marco, Tonini, Giuseppe, Stellato, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6737677/
https://www.ncbi.nlm.nih.gov/pubmed/31528502
http://dx.doi.org/10.1186/s40164-019-0146-9
_version_ 1783450704212393984
author Santini, Daniele
Citarella, Fabrizio
Vincenzi, Bruno
Russano, Marco
Tonini, Giuseppe
Stellato, Marco
author_facet Santini, Daniele
Citarella, Fabrizio
Vincenzi, Bruno
Russano, Marco
Tonini, Giuseppe
Stellato, Marco
author_sort Santini, Daniele
collection PubMed
description The use of direct oral anticoagulant in cancer patients is an emerging issue, which seems to be an alternative to low molecular weight heparin. Every year several new drugs are approved as anticancer treatment with possible drug-drug interaction with other drugs such as oral anticoagulant. We describe, for the first time, a case of neutropenia and thrombocytopenia in a patient in treatment with cabozantinib, a novel anticancer treatment used in metastatic renal cell carcinoma, and apixaban with promptly resumption of the toxicity after the interruption of cabozantinib. This case suggest a possible interaction between these two pharmaceutical agents, which merit caution considering the spreading of the two drugs.
format Online
Article
Text
id pubmed-6737677
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-67376772019-09-16 Cabozantinib and apixaban: an hitherto unreported interaction Santini, Daniele Citarella, Fabrizio Vincenzi, Bruno Russano, Marco Tonini, Giuseppe Stellato, Marco Exp Hematol Oncol Letter to the Editor The use of direct oral anticoagulant in cancer patients is an emerging issue, which seems to be an alternative to low molecular weight heparin. Every year several new drugs are approved as anticancer treatment with possible drug-drug interaction with other drugs such as oral anticoagulant. We describe, for the first time, a case of neutropenia and thrombocytopenia in a patient in treatment with cabozantinib, a novel anticancer treatment used in metastatic renal cell carcinoma, and apixaban with promptly resumption of the toxicity after the interruption of cabozantinib. This case suggest a possible interaction between these two pharmaceutical agents, which merit caution considering the spreading of the two drugs. BioMed Central 2019-09-11 /pmc/articles/PMC6737677/ /pubmed/31528502 http://dx.doi.org/10.1186/s40164-019-0146-9 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Letter to the Editor
Santini, Daniele
Citarella, Fabrizio
Vincenzi, Bruno
Russano, Marco
Tonini, Giuseppe
Stellato, Marco
Cabozantinib and apixaban: an hitherto unreported interaction
title Cabozantinib and apixaban: an hitherto unreported interaction
title_full Cabozantinib and apixaban: an hitherto unreported interaction
title_fullStr Cabozantinib and apixaban: an hitherto unreported interaction
title_full_unstemmed Cabozantinib and apixaban: an hitherto unreported interaction
title_short Cabozantinib and apixaban: an hitherto unreported interaction
title_sort cabozantinib and apixaban: an hitherto unreported interaction
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6737677/
https://www.ncbi.nlm.nih.gov/pubmed/31528502
http://dx.doi.org/10.1186/s40164-019-0146-9
work_keys_str_mv AT santinidaniele cabozantinibandapixabananhithertounreportedinteraction
AT citarellafabrizio cabozantinibandapixabananhithertounreportedinteraction
AT vincenzibruno cabozantinibandapixabananhithertounreportedinteraction
AT russanomarco cabozantinibandapixabananhithertounreportedinteraction
AT toninigiuseppe cabozantinibandapixabananhithertounreportedinteraction
AT stellatomarco cabozantinibandapixabananhithertounreportedinteraction

Ejemplares similares